C. Droz

发表

The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology

Nicholas Moore, Antoine Pariente, Mai Duong, 2017, Pharmacoepidemiology and drug safety.

The CADEUS study: burden of nonsteroidal anti-inflammatory drug (NSAID) utilization for musculoskeletal disorders in blue collar workers.

A. Fourrier-Réglat, N. Moore, M. Rossignol, 2009, British journal of clinical pharmacology.

Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015)

H. Gardarsdottir, P. Souverein, C. Huerta, 2021, Frontiers in Pharmacology.

Interactions Between Amprenavir and the Lopinavir‐ritonavir Combination in Heavily Pretreated Patients Infected with Human Immunodeficiency Virus

F. Clavel, G. Chêne, C. Droz, 2004, Clinical pharmacology and therapeutics.

Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008–2015): A cross‐national drug utilization study

H. Gardarsdottir, P. Souverein, C. Huerta, 2019, British journal of clinical pharmacology.

Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database

A. Pariente, H. Gin, N. Moore, 2012, Diabetologia.

Channelling of COX‐2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study

J. Benichou, M. Sturkenboom, B. Bégaud, 2007, Pharmacoepidemiology and drug safety.

Aspirin and death in Covid-19 A systematic review and meta-analysis

P. Blin, C. Droz, P. Bosco-Lévy, 2021 .

Effectiveness of antibiotics for acute sinusitis in real-life medical practice.

J. Benichou, M. Sturkenboom, N. Moore, 2010, British journal of clinical pharmacology.

Usage patterns of paracetamol in France.

N. Moore, R. Lassalle, F. Salvo, 2016, British journal of clinical pharmacology.

Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens.

P. Morlat, G. Chêne, F. Bonnet, 2000, Journal of acquired immune deficiency syndromes.

The CADEUS study: methods and logistics

J. Benichou, B. Bégaud, M. Amouretti, 2007, Pharmacoepidemiology and Drug Safety.

Pharmacovigilance - The next chapter.

N. Moore, P. Blin, D. Berdaï, 2019, Therapie.

Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France.

A. Pariente, N. Moore, R. Lassalle, 2014, British journal of clinical pharmacology.

Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines

Ehrenstein, H. Gardarsdottir, P. Souverein, 2021 .

Second‐line treatment trends and long‐term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years

G. Leverger, T. Leblanc, Y. Bertrand, 2020, British journal of haematology.

Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample

N. Moore, R. Lassalle, P. Blin, 2018, Drug Safety.

Salvage Therapy with Amprenavir, Lopinavir and Ritonavir 200 Mg/D or 400 Mg/D in HIV-Infected Patients in Virological Failure

F. Clavel, G. Chêne, C. Droz, 2003, Antiviral therapy.

Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS

J. Benichou, N. Moore, Y. Cottin, 2019, American Journal of Cardiovascular Drugs.

Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation

J. Benichou, N. Moore, Y. Cottin, 2019, Clinical pharmacology and therapeutics.

Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation

J. Benichou, N. Moore, Y. Cottin, 2018, British journal of clinical pharmacology.

Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.

J. Benichou, J. Dallongeville, N. Moore, 2019, Atherosclerosis.

Correlations of Soluble Interleukin-2 and Tumor Necrosis Factor Type II Receptors with Immunologic and Virologic Responses Under HAART

R. Salamon, P. Morlat, G. Chêne, 2002, Journal of Clinical Immunology.

Pharmacoepidemiology.

N. Moore, P. Blin, C. Droz, 2019, Handbook of experimental pharmacology.

Pharmacoepidemiology of non-steroidal anti-inflammatory drugs.

N. Moore, P. Blin, Mai Duong, 2019, Therapie.

Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.

F. Brun-Vézinet, B. Masquelier, F. Raffi, 2002, The Journal of infectious diseases.

Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First‐Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study

A. Ravaud, Y. Bécouarn, R. Guimbaud, 2019, Clinical colorectal cancer.

Does Ibuprofen Worsen COVID-19?

B. Carleton, N. Moore, P. Blin, 2020, Drug Safety.

Pharmacoepidemiology

N. Moore, P. Blin, C. Droz, 2019, Concepts and Principles of Pharmacology.

R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing Regimen

B. Masquelier, F. Raffi, B. Spire, 2003, Antimicrobial Agents and Chemotherapy.